Published in Nat Clin Pract Oncol on January 01, 2009
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol (2008) 2.66
Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol (2007) 1.57
Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat (2007) 1.25
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer (2002) 1.20
Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer (2004) 1.14
Why perform sentinel-lymph-node biopsy in patients with melanoma? Nat Clin Pract Oncol (2008) 1.06
Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med (2007) 0.92
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? Lancet (2008) 0.90
How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol (2008) 0.84
Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer (2008) 0.80
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol (2006) 4.88
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol (2008) 3.29
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
[Dithranol in the treatment of scalp psoriasis]. J Dtsch Dermatol Ges (2003) 2.63
Report of a case of Schnitzler's syndrome treated successfully with interferon alpha 2b. Dermatology (2002) 2.37
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol (2007) 1.80
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol (2006) 1.77
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) (2009) 1.76
Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res (2005) 1.65
Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol (2008) 1.59
Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg (2004) 1.58
Nanoparticles--an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm (2006) 1.56
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Immunopathogenesis of psoriasis. Exp Dermatol (2007) 1.44
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A (2009) 1.44
Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol (2006) 1.41
Sunscreens in organ transplant patients. Nephrol Dial Transplant (2008) 1.40
Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int (2014) 1.39
Virtual dermatohistopathology at http://www.pathowiki.org. J Dtsch Dermatol Ges (2012) 1.39
Clinical research in cutaneous T-cell lymphoma moving forward. Arch Dermatol (2008) 1.39
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother (2008) 1.35
40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol (2006) 1.31
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol (2010) 1.29
Porcine ear skin: an in vitro model for human skin. Skin Res Technol (2007) 1.28
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat (2007) 1.25
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer (2006) 1.21
Influence of fast lymphatic drainage on metastatic spread in cutaneous malignant melanoma: a prospective feasibility study. Eur J Nucl Med Mol Imaging (2003) 1.20
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol (2009) 1.19
Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers (2007) 1.19
Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2003) 1.16
PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol (2007) 1.15
Variations of hair follicle size and distribution in different body sites. J Invest Dermatol (2004) 1.15
GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol (2013) 1.14
Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol (2004) 1.14
Immunogenicity of constitutively active V599EBRaf. Cancer Res (2004) 1.12
Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res (2006) 1.12
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res (2003) 1.12
Multiple evolutionary mechanisms drive papillomavirus diversification. Mol Biol Evol (2007) 1.10
The role of hair follicles in the percutaneous absorption of caffeine. Br J Clin Pharmacol (2007) 1.10
IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med (2013) 1.09
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol (2006) 1.08
One-year study on the variation of carotenoid antioxidant substances in living human skin: influence of dietary supplementation and stress factors. J Biomed Opt (2008) 1.08
Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg (2004) 1.07
Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol (2011) 1.06
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res (2007) 1.06
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res (2008) 1.05
Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges (2007) 1.05
Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One (2012) 1.04
Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol (2010) 1.04
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharm Res (2009) 1.04
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol (2006) 1.04
Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature. Eur J Nucl Med Mol Imaging (2006) 1.03
Selective follicular targeting by modification of the particle sizes. J Control Release (2010) 1.03
Genomic characterization of ten novel cutaneous human papillomaviruses from keratotic lesions of immunosuppressed patients. J Gen Virol (2011) 1.03
Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin. Neurochem Res (2002) 1.01
Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol (2009) 1.01
Novel immunotherapies for psoriasis. Trends Immunol (2002) 1.01
Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm (2007) 1.01
Clinical applicability of in vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of nonmelanoma skin cancer. J Biomed Opt (2008) 1.00
Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol (2006) 1.00
Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol Rep (2006) 1.00
Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol (2008) 1.00
Differential stripping: determination of the amount of topically applied substances penetrated into the hair follicles. J Invest Dermatol (2005) 0.99
Current state of vitiligo therapy--evidence-based analysis of the literature. J Dtsch Dermatol Ges (2007) 0.99
Follicular transport route--research progress and future perspectives. Eur J Pharm Biopharm (2008) 0.98
Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs (2008) 0.98
Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg (2004) 0.97
Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol (2007) 0.97
mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant (2010) 0.97
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer (2009) 0.97
Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS One (2011) 0.97
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma. J Exp Med (2011) 0.97
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges (2011) 0.96
Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles. J Invest Dermatol (2006) 0.96
Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol (2006) 0.95
Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine (2005) 0.94